BDBM317972 US10399976, Compound 132::US10807980, Compound 132::US11535614, Compound 132::US9624217, Compound 125::US9624217, Compound 130::US9624217, Compound 131::US9624217, Compound 132

SMILES CC(C)[C@@H]1N(Cc2ccc(cc2)C(F)(F)F)Cc2cc(cnc12)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12

InChI Key InChIKey=BESHYTMQYZRFHG-UHFFFAOYSA-N

Data  16 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 317972   

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2023
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi:  550nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2023
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2023
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to ROR gamma in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2023
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM317972(US9624217, Compound 125 | US9624217, Compound 131 ...)
Affinity DataKi: >1.00E+3nMAssay Description:Compounds of the present invention were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-li...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent